How alcohol and opioids affect HIV medication metabolism
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
This study is looking at how drinking alcohol and using synthetic opioids like fentanyl might change how well HIV medications work, especially a drug called TAF, to help improve treatment for people living with HIV who also use these substances.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10897001 on NIH RePORTER |
What this research studies
This research investigates how the use of alcohol and synthetic opioids, like fentanyl, alters the metabolism of HIV medications, particularly focusing on tenofovir alafenamide fumarate (TAF). It aims to understand the implications of these substances on the effectiveness and safety of anti-HIV drugs, as well as their impact on HIV viral load and patient adherence to treatment. By examining the biochemical interactions and potential new metabolites formed, the study seeks to provide insights that could improve treatment strategies for individuals living with HIV who also use these substances.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV who also engage in alcohol or opioid use.
Not a fit: Patients who do not consume alcohol or opioids and are not affected by HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for HIV patients who consume alcohol or opioids, enhancing their health outcomes.
How similar studies have performed: Previous research has indicated that substance use can significantly impact the metabolism of medications, suggesting that this study's approach is both relevant and necessary.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Yan, Bingfang — University of Cincinnati
- Study coordinator: Yan, Bingfang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.